OBJECTIVE: To investigate the in-vitro antitumor immune responses of dendritoma formed by mouse hepatocellular carcinoma (HCC) cells and lymphotactin (Lptn) gene modified dendritic cells (DCs). METHOD: DCs prepared from mouse bone marrow were genetically modified by lymphotactin adenovirus, and fused with H22 cells by polyethylene glycol (PEG). RT-PCR and ELISA were employed to identify lymphotactin expression at mRNA and protein level. Cell phenotypes and fusion efficiency was detected by FACS. The stimulatory effect of DC on T cells was detected by mixed lymphocyte reaction. The cytotoxicity activity against H22 cells was assayed by LDH method. RESULTS: Lymphotactin could be efficiently expressed by DCLptn/H22 hybridoma. DCLptn/H22 cells could induce potent T cell proliferation effect and generate strong cytotoxic T lymphocyte (CTL) reaction against allogenic H22 cells. CONCLUSION: Lymphotactin genetic modification could enhance the in vitro immune activity of the dendritoma.
OBJECTIVE: To investigate the in-vitro antitumor immune responses of dendritoma formed by mousehepatocellular carcinoma (HCC) cells and lymphotactin (Lptn) gene modified dendritic cells (DCs). METHOD: DCs prepared from mouse bone marrow were genetically modified by lymphotactin adenovirus, and fused with H22 cells by polyethylene glycol (PEG). RT-PCR and ELISA were employed to identify lymphotactin expression at mRNA and protein level. Cell phenotypes and fusion efficiency was detected by FACS. The stimulatory effect of DC on T cells was detected by mixed lymphocyte reaction. The cytotoxicity activity against H22 cells was assayed by LDH method. RESULTS:Lymphotactin could be efficiently expressed by DCLptn/H22 hybridoma. DCLptn/H22 cells could induce potent T cell proliferation effect and generate strong cytotoxic T lymphocyte (CTL) reaction against allogenic H22 cells. CONCLUSION:Lymphotactin genetic modification could enhance the in vitro immune activity of the dendritoma.
Authors: A Soruri; A Fayyazi; C Neumann; T Schlott; T Jung; C Matthes; J Zwirner; J Riggert; J H Peters Journal: Cancer Immunol Immunother Date: 2001-08 Impact factor: 6.968
Authors: T Yoshida; D Izawa; T Nakayama; K Nakahara; M Kakizaki; T Imai; R Suzuki; M Miyasaka; O Yoshie Journal: FEBS Lett Date: 1999-09-10 Impact factor: 4.124
Authors: Peter C R Emtage; Zhou Xing; Yonghong Wan; Albert Zlotnik; Frank L Graham; Jack Gauldie Journal: J Interferon Cytokine Res Date: 2002-05 Impact factor: 2.607